Cart
sales@molnova.com
BMS-1001
CAS No. 2113650-03-4
BMS-1001( BMS 1001 | BMS1001 )
Catalog No. M13359 CAS No. 2113650-03-4
A potent PD-1/PD-L1 interaction inhibitor with IC50 of 2.25 nM in a homogenous time-resolved fluorescence binding assay.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 181 | In Stock |
|
| 5MG | 126 | In Stock |
|
| 10MG | 187 | In Stock |
|
| 25MG | 316 | In Stock |
|
| 50MG | 437 | In Stock |
|
| 100MG | 607 | In Stock |
|
| 200MG | 817 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBMS-1001
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent PD-1/PD-L1 interaction inhibitor with IC50 of 2.25 nM in a homogenous time-resolved fluorescence binding assay.
-
DescriptionA potent PD-1/PD-L1 interaction inhibitor with IC50 of 2.25 nM in a homogenous time-resolved fluorescence binding assay.
-
In Vitro——
-
In Vivo——
-
SynonymsBMS 1001 | BMS1001
-
PathwayImmunology/Inflammation
-
TargetPD-1/PD-L1
-
RecptorPD-1/PD-L1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2113650-03-4
-
Formula Weight631.122
-
Molecular FormulaC35H35ClN2O7
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name(2-((3-cyanobenzyl)oxy)-4-((3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)-5-methylbenzyl)-D-serine
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Guzik K, et al. J Med Chem. 2017 Jul 13;60(13):5857-5867.
2. Chupak, L.S., and Zheng, X. Compounds useful as immunomodulators. PCT/US2014/053695, (2015).
molnova catalog
related products
-
(D)-PPA 1
PD-1/PD-L1 interaction inhibitor. Binds to PD-L1 (Kd = 0.51 μM). Inhibits interaction at 1 mg/mL in flow cytometry. Inhibits tumor growth and prolongs survival time of mice in vivo.
-
Tislelizumab
Tislelizumab (BGB-A317) is an IgG4 class monoclonal antibody targeting human programmed death receptor-1 (PD-1) with antitumor activity that inhibits the binding of Fcγ receptor to macrophages and can be used to study advanced squamous non-small cell lung cancer.
-
Avelumab
Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity.
